Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes.
about
The translational aspect of complementary and alternative medicine for cancer with particular emphasis on KampoUltrasensitive Label-Free Sensing of IL-6 Based on PASE Functionalized Carbon Nanotube Micro-Arrays with RNA-Aptamers as Molecular Recognition Elements.Tissue polypeptide antigen & interleukin-6: Are their serum levels a predictor for response to chemotherapy in breast cancer?Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling.High-level transient expression of ER-targeted human interleukin 6 in Nicotiana benthamianaLycopene enhances antioxidant enzyme activities and immunity function in N-methyl-N'-nitro-N-nitrosoguanidine-enduced gastric cancer ratsRole of β-TrCP ubiquitin ligase receptor in UVB mediated responses in skin.Trial Watch: Immunostimulatory cytokines.STAT3: a potential therapeutic target in dendritic cells for the induction of transplant tolerance.Interleukin-6 in aging and chronic disease: a magnificent pathwayIncreased expression of the androgen receptor with p300 and interleukin-6 coactivators compensate for oligonucleotide suppression of bcl-2: no increased CREB binding protein or interleukin-4 expression.Dangerous exercise: lessons learned from dysregulated inflammatory responses to physical activity.Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells.Inflammation: what role in pediatric cancer?Glutathione in metastases: From mechanisms to clinical applications.Oligonucleotide suppression of bcl-2 in LNCaP cells is compensated by increased androgen sensitivity, p53 and oncogene activity, and suppressed caspase-3.Stress hormones promote growth of B16-F10 melanoma metastases: an interleukin 6- and glutathione-dependent mechanism.Endothelial lipase is upregulated by interleukin-6 partly via the p38 MAPK and p65 NF-κB signaling pathways.Prediction of response to bacillus Calmette-Guérin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio.Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.Depressive symptoms, pain, chronic medical morbidity, and interleukin-6 among primary care patients.
P2860
Q26795520-90E4E0BB-3E97-46A7-B430-5422A5D1F19BQ33844812-039F4097-796A-4DB5-84C8-87CE1B0AD300Q34176287-16D7E7A2-9596-4E4F-9928-895C7530A07AQ34369438-912729D0-3B05-4B02-9C1A-336C92BF668EQ34477570-0A0CBA73-8A82-48CB-87D5-3C31FEAC665BQ34630392-A06831B9-021F-438E-9870-EB4F9B6FE392Q35149273-2CFF3D26-391C-4EE4-AD62-0ADAFC47ABE6Q36057492-C3523C5A-5815-4FF5-9CC9-79EBA2E7EFAAQ36481079-C3249B5A-674A-463C-9A71-1FE2AADF1B13Q36518670-554F5737-8E66-4DAA-A909-D5ABBB963894Q36714276-5A1455CF-CA89-4445-A89D-69FA654DE4DDQ36818172-FD1DBE3B-B58C-441A-A175-30D7E446F0F4Q37641777-E7CAB6ED-6C4F-4C8E-B27E-C550933A6824Q37967667-E0A2780D-CB55-4265-BF15-9500E74FB8D2Q38692702-87B1BD02-CDC9-4537-AD78-096874507AD5Q39151479-52136F9E-A8DB-423C-9470-1147A7FE23F7Q39177632-3AC4FF7E-AB68-47AE-AC8C-F04353951A72Q41521307-E0F31ACE-A75C-4A89-926C-1BB6E5713C56Q41702226-4EA602F3-DFC9-4EF0-8689-630EE5D7860AQ41867620-474232D7-0DAF-44C8-9DD5-41B9799717E5Q45046198-EE4BF7F7-A0F9-4B95-8899-1272D8CA7EB4
P2860
Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Interleukin-6 and new strategi ...... and paraneoplastic syndromes.
@ast
Interleukin-6 and new strategi ...... and paraneoplastic syndromes.
@en
Interleukin-6 and new strategi ...... and paraneoplastic syndromes.
@nl
type
label
Interleukin-6 and new strategi ...... and paraneoplastic syndromes.
@ast
Interleukin-6 and new strategi ...... and paraneoplastic syndromes.
@en
Interleukin-6 and new strategi ...... and paraneoplastic syndromes.
@nl
prefLabel
Interleukin-6 and new strategi ...... and paraneoplastic syndromes.
@ast
Interleukin-6 and new strategi ...... and paraneoplastic syndromes.
@en
Interleukin-6 and new strategi ...... and paraneoplastic syndromes.
@nl
P2860
P356
P1476
Interleukin-6 and new strategi ...... and paraneoplastic syndromes.
@en
P2093
Beverly E Barton
P2860
P304
P356
10.1517/14728222.9.4.737
P407
P577
2005-08-01T00:00:00Z